Business - iData Insights - ReDiscovering Data | Research Reports, News, Events, Research on Demand

Sectors


Price








Published







Business Reports Titles

  • City Profile  Dubai; Comprehensive overview of the city, PEST analysis and analysis of key industries including technology, tourism and hospitality, construction and retail.

    Summary Dubai is one of the seven emirates in the United Arab Emirates (UAE) and is one of the fastest growing cities in the world in terms of population. The region's economy is dominated by the services industries such as wholesale and retail trade; hotels and restaurants; transport, information, telecommunications. Key Findings " ?The service and industry sectors remain the key contributors to the regional economy  and the major employers. " ?Dubai is a key tourist destination for both domestic and international tourists. Specially driven by leisure and business tourists, the sector experienced healthy growth. Strong performance is observed in the construction sector with increasing number of building permits issued and building completions. Synopsis  City Profile  Dubai provides historical and forecast data on key city level metrics along with analytical coverage of the latest political, economic, social, technological, infrastructural, legal and environmental issues affecting Dubai. The report contains detailed tourism, retail, construction, technology and public infrastructure data and insight into economic, social, and industry trends. Reasons?To?Buy " ?Gain a comprehensive knowledge of future economic and demographic trends and understand the performance of various sectors within the city. " ?Analyze and understand the business environment in the city to align your investment and expansion strategies. " ?The report helps to drive a conclusion in choosing a suitable city to invest or expand according to your business structure. " ?Explore new opportunities in the hospitality, tourism, construction, real estate and retail sectors.

    • Release Date: May 31, 2016
    • Price: USD 250
    • Format: PDF

  • Fish & Seafood in India

    Summary Fish & Seafood in India industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the India fish & seafood market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information. Synopsis Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the fish & seafood market in India Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the fish & seafood market in India Leading company profiles reveal details of key fish & seafood market players global operations and financial performance Add weight to presentations and pitches by understanding the future growth prospects of the India fish & seafood market with five year forecasts by both value and volume Macroeconomic indicators provide insight into general trends within the India economy Reasons?To?Buy What was the size of the India fish & seafood market by value in 2015? What will be the size of the India fish & seafood market in 2020? What factors are affecting the strength of competition in the India fish & seafood market? How has the market performed over the last five years? Who are the top competitors in India's fish & seafood market? Key Highlights " The fish & seafood market consists of the retail sale of ambient fish & seafood, processed chilled raw packaged fish & seafood, chilled raw packaged fish & seafood (whole cuts), dried fish & seafood, fresh fish & seafood, and frozen fish & seafood. " The Indian fish and seafood market had total revenues of $23.5m in 2015, representing a compound annual growth rate (CAGR) of 6.1% between 2011 and 2015. " Market consumption volume increased with a CAGR of 5.5% between 2011 and 2015, to reach a total of 8.4 million kilograms in 2015. " The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.8% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $28.3m by the end of 2020.

    • Release Date: May 17, 2016
    • Price: USD 350
    • Format: PDF

  • City Profile  Stockholm; Comprehensive overview of the city, PEST analysis and analysis of key industries including technology, tourism and hospitality, construction and retail.

    Summary Stockholm metropolitan area (also referred to as the Greater Stockholm) is one of three metropolitan areas in Sweden. The area is the largest metropolitan region in the Nordic countries. The city with strong presence of service sector is a key contributor to the Swedish economy contributing about 32% of the national GDP. The region's economy is dominated by tourism, financial intermediation, real estate; wholesale and retail trade; hotels and restaurants. Key Findings " ?The service sectors remain the key contributors to the regional economy  and the major employers. " ?Stockholm is a key tourist destinations among the Nordics, for both domestic and international tourists. The tourism and hospitality sectors experienced healthy growth over the past two years. Strong performance is observed in the construction sector with increasing employment, number of building permits issued and building completions. Synopsis  City Profile  Stockholm provides historical and forecast data on key city level metrics along with analytical coverage of the latest political, economic, social, technological, infrastructural, legal and environmental issues affecting Stockholm. The report contains detailed tourism, retail, construction, technology and public infrastructure data and insight into economic, social, and industry trends. Reasons?To?Buy " ?Gain a comprehensive knowledge of future economic and demographic trends and understand the performance of various sectors within the city. " ?Analyze and understand the business environment in the city to align your investment and expansion strategies. " ?The report helps to drive a conclusion in choosing a suitable city to invest or expand according to your business structure. " ?Explore new opportunities in the hospitality, tourism, construction, real estate and retail sectors.

    • Release Date: January 31, 2016
    • Price: USD 250
    • Format: PDF

  • Allergic Rhinitis - US Drug Forecast and Market Analysis to 2024

    Allergic Rhinitis - US Drug Forecast and Market Analysis to 2024 Summary AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024. In 2014, the base year of the forecast period, AR sales in the US were around $2.8 billion. As in the global markets, this decrease will be fueled mainly by the patent expiries of numerous INCS, and the launch of the first OTC INCS in US pharmacies. Despite the fact that the prevalence of AR patients is set to increase over the forecast period, only one drug will be launched during this time, which is expected to face stiff competition upon entry and capture little market share. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting the US Allergic Rhinitis market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in the US.

    • Release Date: September 01, 2015
    • Price: USD 4995
    • Format: Pdf

  • Allergic Rhinitis - Japan Drug Forecast and Market Analysis to 2024

    e offset by the patent expiry of the best-selling AHs in 2013, and Merck s INCS, Nasonex, in 2017. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Japan from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting Japan Allergic Rhinitis market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in Japan.

    • Release Date: September 01, 2015
    • Price: USD 4995
    • Format: Pdf

  • Allergic Rhinitis - 5EU Drug Forecast and Market Analysis to 2024

    Allergic Rhinitis - 5EU Drug Forecast and Market Analysis to 2024 Summary AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024. In 2014, the base-year of the forecast period, sales of AR products in the 5EU totaled $2.53 billion. The 5EU AR market will remain stagnant, with no major events occurring over the 10-year forecast period. There are no pipeline AR products set to launch in the 5EU during this time. The patent expiries of the best-selling prescription INCS, Nasonex and Nasacort, will be the events that have the most negative impact on the 5EU AR market during the forecast period. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting 5EU Allergic Rhinitis market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in 5EU.

    • Release Date: September 01, 2015
    • Price: USD 6995
    • Format: Pdf

  • Allergic Rhinitis - Current and Future Players

    Allergic Rhinitis - Current and Future Players Summary GlobalData has released its pharma report,  Allergic Rhinitis - Current and Future Players . The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Allergic Rhinitis Market. The report identifies and analyses the key companies shaping and driving the global Allergic Rhinitis market. The report provides insight into the competitive Allergic Rhinitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Investigation of current and future market competition for Allergic Rhinitis - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Allergic Rhinitis sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving Allergic Rhinitis market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What s the next big thing in the global Allergic Rhinitis market landscape? Identify, understand and capitalize

    • Release Date: September 01, 2015
    • Price: USD 2995
    • Format: Pdf

  • Glaucoma - US Drug Forecast and Market Analysis to 2023

    Glaucoma - US Drug Forecast and Market Analysis to 2023 Summary Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie s Rhopressa, Bausch & Lomb s Vesneo (latanoprost bunod), and Inotek s trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market. GlobalData estimates that drug sales for glaucoma in the US during 2013 reached $1.7 billion, making this the largest market within the 7MM. After an initial period of minimal growth, GlobalData estimates that the glaucoma market will follow a steady growth trend from 2018 onwards. This growth is mainly attributed to the expected introduction of five pipeline products during the forecast period, and the overall increase in prevalent cases of glaucoma that is mostly due to an aging society in the US. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Glaucoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the US Glaucoma market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Glaucoma. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the US.

    • Release Date: May 11, 2015
    • Price: USD 4995
    • Format: Pdf

  • Glaucoma - 5EU Drug Forecast and Market Analysis to 2023

    Glaucoma - 5EU Drug Forecast and Market Analysis to 2023 Summary Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie s Rhopressa, Bausch & Lomb s Vesneo (latanoprost bunod), and Inotek s trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market. GlobalData estimates that drug sales for glaucoma in the 5EU reached $250m during the base year of 2013. After an initial period of minimal growth, GlobalData anticipates a moderate and steady growth trend from 2015 onwards. This can be partially attributed to the expected arrival of the recently approved FDC products Simbrinza and Taptiqom during 2015, and to the expected launch of five pipeline products during the forecast period. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Glaucoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting 5EU Glaucoma market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Glaucoma. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in 5EU.

    • Release Date: May 11, 2015
    • Price: USD 6995
    • Format: Pdf

  • Glaucoma - Japan Drug Forecast and Market Analysis to 2023

    Glaucoma - Japan Drug Forecast and Market Analysis to 2023 Summary Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie s Rhopressa, Bausch & Lomb s Vesneo (latanoprost bunod), and Inotek s trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market. GlobalData estimates that drug sales for glaucoma in Japan during 2013 reached $449m, making this the second largest market within the 7MM. GlobalData estimates that the glaucoma market will follow a steady growth trend throughout the forecast period. In part, this can be attributed to the introduction of three new products between 2013 and 2023 that will become a source for positive growth. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Glaucoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Japan from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting Japan Glaucoma market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Glaucoma. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in Japan.

    • Release Date: May 11, 2015
    • Price: USD 4995
    • Format: Pdf


Create Account



Log In Your Account